Watson to open New Jersey R&D center

Wednesday, February 1, 2012 03:37 PM

Watson Pharmaceuticals is planning a global R&D technology center in North Brunswick, N.J. The company has signed a lease for a 32,000-square-foot facility at the Economic Development Authority's Technology Center of New Jersey, a 50-acre complex consisting of lab, production and office space. Watson intends to initially invest approximately $4.5 million in outfitting the new facility.

Watson will immediately retrofit approximately 19,000 square feet of space for product development and analytical laboratories.  The remaining 13,000 square feet will accommodate future expansion.  The facility, which is expected to be completed this spring, will employ approximately 50 scientists, chemists, engineers and support staff. 

"The location of the new Global R&D Technology Center will enable Watson to leverage our proximity to such educational centers of excellence as Rutgers University,” said Paul Bisaro, president and CEO of Watson. “This will enable Watson to establish collaborations with university departments including pharmaceutics, chemistry and engineering and permit us to benefit from the talent pool in the heart of the pharmaceutical industry of New Jersey.” 

The new center will become Watson's state-of-the-art facility for developing generic pharmaceutical products, in particular for inhalation technology and respiratory products, with the ability to conduct formulation development and analytical testing, Bisaro said.

In early 2010, Watson relocated its global corporate headquarters to Parsippany, N.J., in a facility designed to support its global expansion and ultimately employ as many as 500 people.

With its new location, Watson joins companies including Merial, Chromocell and Rutgers Technology Center.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs